Condition
Asherman's Syndrome
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Recruiting1
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06450301RecruitingPrimary
Senescent Endometrial Cells in Patients with Thin Endometrial Lining
NCT02825849Phase 2Terminated
Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair
NCT03223454Phase 1UnknownPrimary
Human Amniotic Epithelial Cells for Asherman's Syndrome
NCT02708277Not ApplicableCompletedPrimary
Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions
NCT02144987Phase 4CompletedPrimary
Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy
Showing all 5 trials